Autoantibodies to M2-cholinoreceptors as a potential development factor of arrhythmia in patients with paroxysmal atrial fibrillation

Mironova, E S; Сергеевна, Миронова Екатерина; Миронова, Н. А.; Александровна, Миронова Наталия; Шарф, Т. В.; Васильевна, Шарф Татьяна; Ефремов, Е. Е.; Евгеньевич, Ефремов Евгений; Азьмуко, А. А.; Андреевич, Азьмуко Андрей; Молокоедов, А. С.; Сергеевич, Молокоедов Александр; Zykov, K. A.; Алексеевич, Зыков Кирилл; Golitsyn, S. P.; Павлович, Голицын Сергей

doi:10.26442/00403660.2019.09.000280

Cited by 3 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients suffering from lone paroxysmal AF had a higher prevalence of increased levels of anti-M2 antibodies compared to patients with both AF and AH. However, there was no difference in the prevalence of increased levels of anti-M2 immunoglobulin M (IgM) between these groups [38].…”

Section: Research Investigating Only Anti-m2 Antibodiesmentioning

confidence: 97%

Autoantibodies in Atrial Fibrillation—State of the Art

Zygadło

Procyk

Balsam

et al. 2023

IJMS

View full text Add to dashboard Cite

Atrial fibrillation (AF) is the most common type of cardiac arrhythmia. To date, a lot of research has been conducted to investigate the underlying mechanisms of this disease at both molecular and cellular levels. There is increasing evidence suggesting that autoimmunity is an important factor in the initiation and perpetuation of AF. Autoantibodies are thought to play a pivotal role in the regulation of heart rhythm and the conduction system and, therefore, are associated with AF development. In this review, we have summarized current knowledge concerning the role of autoantibodies in AF development as well as their prognostic and predictive value in this disease. The establishment of the autoantibody profile of separate AF patient groups may appear to be crucial in terms of developing novel treatment approaches for those patients; however, the exact role of various autoantibodies in AF is still a matter of ongoing debate.

show abstract

Section: Research Investigating Only Anti-m2 Antibodiesmentioning

confidence: 97%

Autoantibodies in Atrial Fibrillation—State of the Art

Zygadło

Procyk

Balsam

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using domestic antiarrhythmic drug Refralon. Initial clinical results

Dzaurova¹,

Mironov²,

Shubik³

et al. 2021

Kardio. vestn.

View full text Add to dashboard Cite

Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety

Mironov

Shubik

Vlodzyanovskiy

et al. 2021

Racionalʹnaâ farmakoterapiâ v kardiologii

View full text Add to dashboard Cite

Aim. We aimed to assess safety and effectiveness of class III antiarrhythmic drug Refralon for conversion of atrial fibrillation (AFib) and flutter (AFl) in post-registration trial and to compare data of primary center (National medical research center in cardiology) with data of other hospitals.Material and Methods. We performed retrospective cohort study in 727 patients (451 enrolled in primary center and 276 enrolled in other hospitals) admitted between June 24, 2014 and June 24, 2019. Refralon was administered for conversion of AFib and AFl in intense care units in escalating doses (10-30 micrograms/kg) intravenously.Results. Conversion of AFib and AFl into sinus rhythm was achieved in 53,6% after administration of 10 mcg/kg dose, in 73% after administration of 20 mcg/kg dose and in 91,6% after administration of Refralon in dose up to 30 mcg/kg. No mortality and no major adverse cardiac events registered in our study. Asystole >3.0 sec observed in 5% (35 of 727) of patients): in 5% (24 of 451) of patients enrolled in primary center and in 4% (11 of 276) of patients enrolled in other hospitals; 95% confidence interval (CI) [-0.09; 0.113]. Asystole> 5.0 s observed in 1.7% of patients who further required non-urgent implantation of a permanent pacemaker due to manifestations of sinus node dysfunction. Cardiac conduction disturbances (exclusively sinus bradycardia) were registered in 7% (53 of 727) patients: in 8% (37 of 451) of patients enrolled in primary center and in 6% (17 of 276) of patients enrolled in other hospitals; 95% CI: [-0.1; 0.15]. Only 0.14% of patients had symptomatic sinus bradycardia that resolved after atropine injection. Ventricular arrhythmias (exclusively Torsade de pointes tachycardia in excessive QT interval prolongation) were registered in 1.7% (12 of 727) patients: in 2% (9 of 451) of patients in primary center and in 1% (3 of 276) of patients of other hospitals; 95% CI: [-0.06; 0.08]. QTc interval prolongation to values >500 ms documented in 19% (138 of 727) of patients: in 21% (95 of 451) of patients in primary center and in 16% (43 of 276) of patients in other hospitals; 95% CI: [-0.13; 0.24].Conclusion: In post-registration multicenter trial Refralon demonstrated good safety profile in conversion of AFib and AFl. Potential risk of TdP tachycardia mandates precautions with the use of the drug. In other hospitals Refralon did not demonstrate lower safety than in primary medical center.

show abstract

Autoantibodies to M2-cholinoreceptors as a potential development factor of arrhythmia in patients with paroxysmal atrial fibrillation

Cited by 3 publications

References 24 publications

Autoantibodies in Atrial Fibrillation—State of the Art

Autoantibodies in Atrial Fibrillation—State of the Art

Efficiency and safety of the modified protocol for cardioversion of atrial fibrillation using domestic antiarrhythmic drug Refralon. Initial clinical results

Safety and Effectiveness of Pharmacologic Conversion of Atrial Fibrillation and Flutter: Results of Multicenter Trial. Part II: Assessment of Safety

Contact Info

Product

Resources

About